ÅÄÂå¡¡»ÖÌç¡¡¡ÊTASHIRO Shimon¡Ë
1976ǯ9·îÀ¸¤Þ¤ì¡£2000ǯ3·î¡¢ÅìËÌÂç³Øʸ³ØÉô´¡£2007ǯ3·î¡¢ÅìËÌÂç³ØÂç³Ø±¡Ê¸³Ø¸¦µæ²ÊÇî»Î¸å´ü²ÝÄø½¤Î»¡£Çî»Î¡Êʸ³Ø¡Ë¡£ÆüËܳؽѿ¶¶½²ñÆÃÊ̸¦µæ°÷¡¢ÅìµþÂç³ØÂç³Ø±¡°å³Ø·Ï¸¦µæ²ÊÆÃǤ½õ¶µ¡¢¾¼ÏÂÂç³Ø¸¦µæ¿ä¿Ê¼¼¹Ö»Õ¡¢¹ñΩ¤¬¤ó¸¦µæ¥»¥ó¥¿¡¼À¸Ì¿ÎÑÍýÉôŤò·Ð¤Æ¸½ºß¡¢ÅìËÌÂç³ØÂç³Ø±¡Ê¸³Ø¸¦µæ²Ê¶µ¼ø¡£ÀìÌç¤Ï¡¢°åÎżҲñ³Ø¡¢»à¤Î¼Ò²ñ³Ø¡¢À¸Ì¿ÎÑÍý³Ø¡£
¼çÍ׶ÈÀÓ
Ãø½ñ¡ÎñÃø¡Ï
- 2020,¡Ø¤ß¤ó¤Ê¤Î¸¦µæÎÑÍýÆþÌ硽Î×¾²¸¦µæ¤Ë¤Ê¤¼¤³¤ó¤ÊÌÌÅݤʼ곤¤¬É¬ÍפʤΤ«¡Ù°å³Ø½ñ±¡
- 2016,¡Ø»à¤Ë¤æ¤¯²áÄø¤òÀ¸¤¤ë¡½½ªËö´ü¤¬¤ó´µ¼Ô¤Î·Ð¸³¤Î¼Ò²ñ³Ø¡ÙÀ¤³¦»×ÁÛ¼Ò
- 2011,¡Ø¸¦µæÎÑÍý¤È¤Ï²¿¤«¡½Î×¾²°å³Ø¸¦µæ¤ÈÀ¸Ì¿ÎÑÍý¡ÙÒ¦Áð½ñ˼
Ãø½ñ¡Î¶¦Ãø¡Ï
- 2023,¡ØÎ×¾²¸½¾ì¤Î¤â¤ä¤â¤ä¤ò²ò¤¤Û¤°¤¹¡½´ËÏÂ¥±¥¢¡ßÀ¸Ì¿ÎÑÍý¡ß¼Ò²ñ³Ø¡Ù°å³Ø½ñ±¡¡Ê¿¹ÅÄãÌé¤È¤Î¶¦Ãø¡Ë
Ãø½ñ¡ÎÊÔÃø¡Ï
- 2023,¡ØÄÃÀŤȰ³ڻà¤Î¥°¥ì¡¼¥¾¡¼¥ó¤òÌ䤦¡½°å³Ø¡¦´Ç¸î³Ø¡¦À¸Ì¿ÎÑÍý³Ø¡¦Ë¡³Ø¤Î»ëÅÀ¡ÙÃæ³°°å³Ø¼Ò¡Ê¿¹ÅÄãÌé¤È¤Î¶¦ÊÔ¡Ë
- 2022,¡Ø¸½ÂåÆüËܤΡִǼè¤êʸ²½¡×¤ò¹½ÁÛ¤¹¤ë¡ÙÅìµþÂç³Ø½ÐÈDzñ¡ÊÉ⥱빬Â塦»³ÅÄ¿µÌé¤È¤Î¶¦ÊÔ¡Ë
- 2022,¡ØÎ×¾²ÎÑÍý¤Î¹Í¤¨Êý¤È¼ÂÁ©¡½°åÎÅ¡¦¥±¥¢¥Á¡¼¥à¤Î¤¿¤á¤Î»öÎ㸡Ƥˡ¡ÙÅìµþÂç³Ø½ÐÈDzñ¡ÊÀ¶¿åůϺ¡¦²ñÅÄ·°»Ò¤È¤Î¶¦ÊÔ¡Ë
Ãø½ñ¡Îʬô¼¹É®¡Ï
- 2024,¡Ö¡Ö¾Ú¸À¡×¤È¤·¤Æ¤Îɤ¤¤Î¸ì¤ê¡½»à¤Ë¤æ¤¯¿Í¤Î¸ì¤ê¤ò¤É¤¦Ê¹¤¯¤«¡×Àõ¸«ÍΡ¦ÂãÃÒ¹§¡¦¹â¶¶ºßÌ顦Ĺ¹¾¹°»Ò¡¦Ê¿¸¶º¸Åͻ֡¦ÅçÅÄÀéÊæÊÔ¡Ø¥¨¥ó¥É¥ª¥Ö¥é¥¤¥Õ¥±¥¢³Ø¡½¡É¼«Ê¬¤é¤·¤¯À¸¤¤ë¡Éů³Ø¡ÙÆüËܴǸ²ñ½ÐÈDzñ,125-134.
- 2023,¡Ö»ý³Ū¿¼¤¤ÄÃÀŤÎÎÑÍý¡½°Â³Ú»à¤È²¿¤¬°ã¤¦¤Î¤«¡×¿¹ÅÄãÌ顦ÅÄÂå»ÖÌçÊÔ¡ØÄÃÀŤȰ³ڻà¤Î¥°¥ì¡¼¥¾¡¼¥ó¤òÌ䤦¡½°å³Ø¡¦´Ç¸î³Ø¡¦À¸Ì¿ÎÑÍý³Ø¡¦Ë¡³Ø¤Î»ëÅÀ¡ÙÃæ³°°å³Ø¼Ò,160-177.
- 2023,¡Ö¶ìÄË´ËÏ¤Τ¿¤á¤ÎÄÃÀÅ¡½ÏÀÅÀ¤Ï²¿¤«¡©¡×¿¹ÅÄãÌ顦ÅÄÂå»ÖÌçÊÔ¡ØÄÃÀŤȰ³ڻà¤Î¥°¥ì¡¼¥¾¡¼¥ó¤òÌ䤦¡½°å³Ø¡¦´Ç¸î³Ø¡¦À¸Ì¿ÎÑÍý³Ø¡¦Ë¡³Ø¤Î»ëÅÀ¡ÙÃæ³°°å³Ø¼Ò,252-270¡Ê¿¹ÅÄãÌé¤È¤Î¶¦Ãø¡Ë.
- 2023,¡ÖÌô³²¥¹¥â¥ó¡¼¡Öɤó¤Ç¤¤¤ë¼Ò²ñ¡×¤Îȯ¸«¡×Ëܶ¿ÀµÉ𡦺´Æ£Å¯É§ÊÔ¡ØÌô³²¤È¤Ï²¿¤«¡½¿·¤·¤¤Ìô³²¤Î¼Ò²ñ³Ø¡Ù¥ß¥Í¥ë¥ô¥¡½ñ˼,94-111.
- 2022,¡Ö¡Ö»à¤Î¸¦µæ¡×¤Î¸½ºß¡½¿ÍÎà³Ø¡¦¼Ò²ñ³Ø¤Î·ÏÉ褫¤é¡×É⥱빬Â塦ÅÄÂå»ÖÌ硦»³ÅÄ¿µÌéÊԡظ½ÂåÆüËܤΡִǼè¤êʸ²½¡×¤ò¹½ÁÛ¤¹¤ë¡ÙÅìµþÂç³Ø½ÐÈDzñ,3-27¡ÊÅÄÃæÂç²ð¤È¤Î¶¦Ãø¡Ë.
- 2022,¡Ö´Ç¼è¤ê¤Ë¤ª¤±¤ë¡ÖËܿͤΰոþ¤Îº½Å¡×¤È¤Ï¡½É¤¤¤Î¸ì¤ê¸¦µæ¤«¤é°Õ»×·èÄê»Ù±ç¤Ø¡×É⥱빬Â塦ÅÄÂå»ÖÌ硦»³ÅÄ¿µÌéÊԡظ½ÂåÆüËܤΡִǼè¤êʸ²½¡×¤ò¹½ÁÛ¤¹¤ë¡ÙÅìµþÂç³Ø½ÐÈDzñ,79-101.
- 2022,¡ÖMCD¤ÎÃ諤òÍѤ¤¤ë»öÎ㸡Ƥˡ¡×À¶¿åůϺ¡¦²ñÅÄ·°»Ò¡¦ÅÄÂå»ÖÌçÊÔ¡ØÎ×¾²ÎÑÍý¤Î¹Í¤¨Êý¤È¼ÂÁ©¡½°åÎÅ¡¦¥±¥¢¥Á¡¼¥à¤Î¤¿¤á¤Î»öÎ㸡Ƥˡ¡ÙÅìµþÂç³Ø½ÐÈDzñ,128-134.
- 2022,¡Öɱ¡ÁÈ¿¥¤Ë¤ª¤±¤ëÎÑÍý¥µ¥Ý¡¼¥ÈÂÎÀ©¡×À¶¿åůϺ¡¦²ñÅÄ·°»Ò¡¦ÅÄÂå»ÖÌçÊÔ¡ØÎ×¾²ÎÑÍý¤Î¹Í¤¨Êý¤È¼ÂÁ©¡½°åÎÅ¡¦¥±¥¢¥Á¡¼¥à¤Î¤¿¤á¤Î»öÎ㸡Ƥˡ¡ÙÅìµþÂç³Ø½ÐÈDzñ,135-141.
- 2021,¡ÖÈ︳¼Ô¤ÎÊݸb.¼éÈëµÁ̳¤È¸Ä¿Í¾ðÊóÊݸî¡×¡ÖÈ︳¼Ô¤ÎÊݸc.ÇÛθ¤¬É¬Íפʴµ¼Ô¤Ø¤ÎÂбþ¡×°ìÈ̼ÒÃÄË¡¿ÍÆüËÜÎ×¾²ÌôÍý³Ø²ñÊÔ½¸¡ØCRC¥Æ¥¥¹¥È¥Ö¥Ã¥¯¡¡Âè4ÈÇ¡Ù°å³Ø½ñ±¡,42-47.
- 2020,¡Ö°åΟ½¾ì¤Ë¤ª¤±¤ëÎ×¾²ÎÑÍý¥µ¥Ý¡¼¥ÈÂÎÀ©¤Î¹½ÃÛ¡½¡ÖÎ×¾²ÎÑÍý¥³¥ó¥µ¥ë¥Æ¡¼¥·¥ç¥ó¡¦¥µ¡¼¥Ó¥¹³«»Ï¤Î¤¿¤á¤Î10¤Î¥¹¥Æ¥Ã¥×¡×ºîÀ®¤Î»î¤ß¡×Ëܼϵ×ÊÔ¡ØÆüËܤιâ²ÁÃÍ°åÎÅ¥·¥ê¡¼¥º6¡¡¥³¥ß¥å¥Ë¥±¡¼¥·¥ç¥ó¤ÈÎÑÍý¤Î¥Ï¥¤¥Ð¥ê¥å¡¼¥±¥¢¡½¼«¸Ê³Ø½¬¤ËÌòΩ¤Ä23¾ÉÎã¡Ù¥«¥¤½ñÎÓ,9-31¡Ê°ì²È¹ËË®¡¦Î¤¸«³¨Íý»Ò¡¦À¶¿åÀé²Â»Ò¤È¤Î¶¦Ãø¡Ë.
- 2020,¡Ö¸¦µæÎÑÍý¤Î´ðËÜŪ¤Ê¹Í¤¨Êý¡×ÍÅıٻҡ¦ÂΩÃÒ¹§ÊÔ¡ØÌô³Ø¿Í¤Î¤¿¤á¤Î»öÎã¤Ç³Ø¤ÖÎÑÍý³Ø¡ÙÆƲ,80-90.
- 2020,¡ÖÎ×¾²ÎÑÍý¡×ÉúÌÚ¿®¼¡¡¦³ß§¾Ï¡¦ÁúÅĵáÊÔ¡ØÀ¸Ì¿ÎÑÍý¤È°åÎÅÎÑÍý¡¡Âè4ÈÇ¡Ù¶â˧Ʋ,36-48.
- 2019,¡ÖÎ×¾²¸¦µæË¡¤ÎÂоÝÈϰϡסÖǧÄêÎ×¾²¸¦µæ¿³ºº°Ñ°÷²ñ¤ÎÍ×·ï¡×Æ£¸¶¹¯¹°Êԡظ½¾ì¤Ç»È¤¨¤ëÎ×¾²¸¦µæË¡¡ÙÆƲ,17-28,124-131.
- 2019,¡ÖÎÑÍý 1. ³µÏÀ¡×¡ÖÎÑÍý 3. ¸¦µæÂоݼԤÎÁªÂò¡×ÆüËܺÆÀ¸°åÎųزñ´Æ½¤¡Ø¥Æ¥¥¹¥È¥Ö¥Ã¥¯ºÆÀ¸°åÎÅ¡½ÁϤ롢¹Ô¤¦¡¢»Ù¤¨¤ë¡×ÆüËܺÆÀ¸°åÎųزñ,59-67,79-86.
- 2018,¡ÖÆüËܤˤª¤±¤ëÎÑÍý¿³ºº°Ñ°÷²ñÀ©ÅÙ²þ³×¤ÎÆ°¸þ¡½¸¦µæÎÑÍý»Ø¿Ë¤«¤éÎ×¾²¸¦µæË¡¤Ø¡×¸ø±×ºâÃÄË¡¿Í°åÎŲʳظ¦µæ½ê´Æ½¤¡ØÅ°Ä츦µæ¡¡¡Ö¼£¸³¡×¤È¡ÖÎ×¾²¡×¡ÙË¡¸¦, 161-185¡ÊÏÀʸ¤ÎºÆÏ¿¡Ë.
- 2018,¡Ö¡Ö¼Â¸³Åª¡×¤Ê¼ê½Ñ¡½»¥ËÚ¥í¥Ü¥È¥ß¡¼»ö·ï¡×¡Ö¸¦µæ¤È¿ÇÎŤζ³¦¤ò¹Í¤¨¤ë¡½¡Ö³×¿·Åª¼£ÎšפεöÍƾò·ï¡×°æ¾åͪÊ塦°ì²È¹ËË®ÊÔ¡Ø°å³Ø¸¦µæ¡¦Î×¾²»î¸³¤ÎÎÑÍý¡½¤ï¤¬¹ñ¤Î»öÎã¤Ë³Ø¤Ö¡×ÆüËÜɾÏÀ¼Ò, 52-64,84-88.
- 2018,¡Ö¤¬¤ó°åÎŤÈÎ×¾²»î¸³¤Ë¤ª¤±¤ëÎÑÍýŪ¸¶Â§¡×ÆüËÜÎ×¾²¼ðáç³Ø²ñÊÔ¡Ø¿·Î×¾²¼ðáç³Ø¡½¤¬¤óÌôʪÎÅË¡ÀìÌç°å¤Î¤¿¤á¤Ë¡¡²þÄûÂè5ÈÇ¡ÙÆƲ,149-153¡¥
- 2018,¡Öɱ¡¤ÎÊý¿Ë¤È¤·¤Æ¡Ö¸ÆµÛ´ï¤Ï³°¤·¤Þ¤»¤ó¡×¤ÈÄê¤á¤ë¤³¤È¤ÏÎÑÍýŪ¤Ëµö¤µ¤ì¤ë¤Î¤«¡×Àõ°æÆÆ¡¦¾®À¾·ÃÈþ»Ò¡¦ÂçËÌÁ´½ÓÊÔ¡ØÎÑÍýŪ¤Ë¹Í¤¨¤ë°åÎŤÎÏÀÅÀ¡ÙÆüËܴǸ²ñ½ÐÈDzñ, 149-155.
- 2016,¡ÖÎ×¾²¸¦µæ¤ÎÎÑÍý¤Èµ¬À©¡×¿å뽤µª´Æ½¤¡¿ÂΩÁ԰졦ËÙÉô·É»°¡¦Ê¡ß·ÀµÍΡ¦¿¿Éô½ß¡¦¾®ÀîÀéÅÐÀ¤¡¦ÂíËÜůÌ顦ã·Æ£ÌÀ»ÒÊԡؤ褯¤ï¤«¤ëÎ×¾²¸¦µæ¡½¾®»ù¤¬¤ó¡Ù°åÌô¥¸¥ã¡¼¥Ê¥ë,36-46.
- 2015,¡Ö±Ö³Ø¸¦µæ¤ÎÎÑÍý¡×ÀÖÎÓϯ¡¦»ù¶ÌÁïÊÔ¡ØÆþÌ硦°åÎÅÎÑÍýIII¡¡¸ø½°±ÒÀ¸ÎÑÍý¡ÙÒ¦Áð½ñ˼,215-41.¡Ê¾¾°æ·ò»Ö¤È¤Î¶¦Ãø¡Ë
- 2014,¡ÖÎ×¾²»àÀ¸³Ø¤ÎÌ䤤¤ÈÊýË¡¡×Î×¾²»àÀ¸³Ø¥Æ¥¥¹¥ÈÊÔ½¸°Ñ°÷²ñÊԡإƥ¥¹¥ÈÎ×¾²»àÀ¸³Ø¡ÙÒ¦Áð½ñ˼,33-43.
- 2013,¡Ö°åÎÅ¡¦´Ç¸î¡½É¤¤¤È¥±¥¢¤Î·Ð¸³¤òµ½Ò¤¹¤ë¡×Æ£ÅÄ·ë»Ò¡¦Ë̼ʸÊԡظ½Â奨¥¹¥Î¥°¥é¥Õ¥£¡¼¡½¿·¤·¤¤¥Õ¥£¡¼¥ë¥É¥ï¡¼¥¯¤ÎÍýÏÀ¤È¼ÂÁ©¡Ù¿·Í˼Ò,158-65.
- 2012,¡Ö»à¤Ë¤æ¤¯²áÄø¤ò¤É¤¦À¸¤¤ë¤«¡½»ÜÀߤȺßÂð¤ÎÆó¼ÔÂò°ì¤òĶ¤¨¤Æ¡×°ÂÆ£Âٻꡦ¹â¶¶ÅÔÊÔ¡Ø¥·¥ê¡¼¥ºÀ¸Ì¿ÎÑÍý³ØÂè4´¬ ½ªËö´ü°åÎÅ¡Ù´ÝÁ±,108-25.
- 2012,¡Ö̤·è¤ÎÌ䤤¤È¤·¤Æ¤Î¤¬¤ó¹ðÃΡ½¤½¤Î¸å¤òÀ¸¤¤ë´µ¼Ô¤Î¸ì¤ê¤«¤é¡×»°°æ¤µ¤è¡¦ÎëÌÚÃÒÇ·ÊÔÃø¡Ø¥±¥¢¤Î¥ê¥¢¥ê¥Æ¥£¡½¶³¦¤òÌ䤤¤Ê¤ª¤¹¡ÙË¡À¯Âç³Ø½ÐÈǶÉ,201-32.
- 2011,¡Ö¥Ù¥ë¥â¥ó¥È¡¦¥ì¥Ý¡¼¥È¤ÎÎÑÍý¸¶Â§¡×¡Öº¸·À¤Ë°¤¹¤ë¤³¤È¡×ºû·ª½ÓÇ·¡¦ÃÓ¾¾½¨Ç·ÊÔ¡ØÎ×¾²¸¦µæ¤Î¤¿¤á¤ÎÎÑÍý¿³ºº¥Ï¥ó¥É¥Ö¥Ã¥¯¡Ù´ÝÁ±½ÐÈÇ,42-44,115-25.¡Ê°æ¾åͪÊå¤È¤Î¶¦Ãø¡Ë
- 2011,¡ÖºÇ´ü¤Þ¤ÇÀ¸¤¤ë¤¿¤á¤Ë¡½¥Û¥¹¥Ô¥¹¡¦´ËÏÂ¥±¥¢¤Î¸½¾ì¤«¤é¡×¶Ì°æ¿¿Íý»Ò¡¦Âç뤤¤Å¤ßÊԡؤϤ¸¤á¤Æ½Ð²ñ¤¦À¸Ì¿ÎÑÍý¡ÙÍÈå³Õ,167-85.
- 2010,¡ÖÀìÌ翦¤Î¡Ö¼«Î§¡×¤Îž´¹¡½°å³Ø¸¦µæ¤ò´Æ»ë¤¹¤ë¤Î¤Ï狼¡×ÃçÀµ¾»¼ùÊÔ¡ØÁѽñ¥¢¥ì¥Æ¥¤¥¢12¡¡¼«Í³¤È¼«Î§¡Ù¸æÃã¤Î¿å½ñ˼,273-99.
- 2010,¡ÖÌô¤Îµ¬À©¡×¡Ö¥¿¥ë¥³¥Ã¥È¡¦¥Ñ¡¼¥½¥ó¥º¡×¡Ö¿ÍÂμ¸³¡×¡ÖÀ¸Ì¿ÎÑÍý¡×ÃæÀɧ¡¦¹õÅĹÀ°ìϺÊÔÃø¡Ø¤è¤¯¤ï¤«¤ë°åÎżҲñ³Ø¡Ù¥ß¥Í¥ë¥ô¥¡½ñ˼,92-3,164-7,178-83.
- 2010,¡Ö¸«¤¨¤ë½¡¶µ ¸«¤¨¤Ê¤¤½¡¶µ¡½Ä¶±ÛÀ¤Î¥À¥¤¥Ê¥ß¥º¥à¡×Ááºä͵»Ò¡¦¹°æÎÉŵ¡¦Å·Åľë²ðÊÔÃø¡Ø¼Ò²ñ³Ø¤Î¤Ä¤Ð¤µ¡½°åÎÅ¡¦´Ç¸î¡¦Ê¡»ã¤ò³Ø¤Ö¿Í¤Î¤¿¤á¤Ë¡Ù¥ß¥Í¥ë¥ô¥¡½ñ˼,123-41.¡Ê½ô²¬Î»²ð¤È¤Î¶¦Ãø¡Ë
- 2009,¡Ö¼õ¤±·Ñ¤¬¤ì¤Æ¤¤¤¯À¸¡×À¶¿åůϺ´Æ½¤¡¿²¬Éô·ò¡¦ÃÝÇ·Æâ͵ʸÊԡؤɤ¦À¸¤ ¤É¤¦»à¤Ì¤«¡½¸½¾ì¤«¤é¹Í¤¨¤ë»àÀ¸³Ø¡ÙµÝÀý½ñ±¡,227-44.
- 2009,¡ÖÃæÀä¤ÈÂÛ»ù¸¦µæ¤ÎÎÑÍý¡½Á´ÊÆ°Ñ°÷²ñ¤ÎµÄÏÀ¤ò¤Æ¤¬¤«¤ê¤È¤·¤Æ¡×¶Ì°æâÃÍý»Ò¡¦Ê¿ÄÍ»ÖÊÝÊԡؼΤƤé¤ì¤ë¤¤¤Î¤Á¡¢ÍøÍѤµ¤ì¤ë¤¤¤Î¤Á¡½ÂÛ»ùÁÈ¿¥¤Î¸¦µæÍøÍѤÈÀ¸Ì¿ÎÑÍý¡ÙÀ¸³è½ñ±¡,75-103.
- 2008,¡Ö»à¤ÎÎ×¾²¤Ë¤ª¤±¤ëÀ¤Âå·Ñ¾µÀ¤ÎÌäÂ꡽¤¢¤ëºßÂ𤬤󴵼ԤΥ饤¥Õ¥¹¥È¡¼¥ê¡¼¡×ºù°æ¸ü¡¦»³ÅÄÉÙ½©¡¦Æ£°æÂÙÊԡزáµî¤ò˺¤ì¤Ê¤¤¡½¸ì¤ê·Ñ¤°·Ð¸³¤Î¼Ò²ñ³Ø¡Ù¤»¤ê¤«½ñ˼,139-56.
- 2008,¡Ö°å»Õ¤Î»ëÅÀ¤«¤é¤ß¤¿¸¦µæÎÑÍý¡½¶âÂôÂç³ØÉհɱ¡ÌµÃÇÎ×¾²»î¸³Áʾ٤ò»öÎã¤È¤·¤Æ¡×¿ùÅÄÊƹÔÊÔ¡ØÆüÊƤΰåÎÅ¡½À©ÅÙ¤ÈÎÑÍý¡ÙÂçºåÂç³Ø½ÐÈDzñ,129-50.
- 2007,¡Ö¡Ö´Ç¼è¤ê¡×¤ò»Ù¤¨¤ë»Ô̱³èÆ°¡½¥Û¥¹¥Ô¥¹¥Ü¥é¥ó¥Æ¥£¥¢¤Î¸½¾ì¤«¤é¡×À¶¿åůϺÊԡعâÎð¼Ò²ñ¤òÀ¸¤¤ë¡½Ï·¤¤¤ë¿Í¡¿´Ç¼è¤ë¥·¥¹¥Æ¥à¡ÙÅ쿮Ʋ,117-38.
- 2004,¡Ö½¡¶µ¤ÈÎÑÍý¡½¸½Âå¼Ò²ñ¤Ë¤ª¤±¤ë¡ÖÀ»¤Ê¤ë¤â¤Î¡×¤Î¤æ¤¯¤¨¡×Ááºä͵»Ò¡¦¹°æÎÉŵÊÔÃø¡Ø¤ß¤é¤¤¤òÂ󤯼Ҳñ³Ø¡½´Ç¸î¡¦Ê¡»ã¤ò³Ø¤Ö¿Í¤Î¤¿¤á¤Ë¡Ù¥ß¥Í¥ë¥ô¥¡½ñ˼,86-101.
ÏÀʸ
- 2023,¡Ö°åΞðÊó¤Î¸¦µæÍøÍѤ˴ؤ¹¤ëµ¬À©¤Î¸½¾õ¤È²ÝÂ꡽¡Ö¾ðÊó¤Î²Ã¹©¡×¤È¡ÖÌÜŪ¤Î¸ø±×À¡×¤ÎÆóʬˡ¤òĶ¤¨¤Æ¡×¡ØÆüËÜÃκâ³Ø²ñ»ï¡Ù20(2):21-30.
- 2023,¡ÖÌ̲ñÀ©¸Â¤ÎÎÑÍý¡½¥Ñ¥ó¥Ç¥ß¥Ã¥¯²¼¤Ç¡Ö¿Í¤È²ñ¤¦¤³¤È¡×¤Î°ÕÌ£¤òÌ䤤ľ¤¹¡×¡Øʸ²½¡Ù86(3,4):74-93.
- 2023,"Difficulties in Ensuring Review Quality Performed by Committees under the Act on the Safety of Regenerative Medicine in Japan"Stem Cell Reports 18(3):613-617(co-authored with Ikka Tsunakuni et al.).
- 2022,"Survey Results and Recommendations from Japanese Stakeholders for Good Clinical Practice Renovation," Therapeutic Innovation & Regulatory Science 56(2):220-229(co-authored with Kenichi Nakamura et al.).
- 2021, "A Systematic Approach to the Disclosure of Genomic Findings in Clinical Practice and Research: A Proposed Framework with Colored Matrix and Decision-making Pathways." BMC Medical Ethics 22,168 (co-authored with Kenji Matsui, Keiichiro Yamamoto, and Tomohide Ibuki).
- 2021,"Medical Guidelines for Li-Fraumeni Syndrome 2019, Version 1.1.," International Journal of Clinical Oncology, 26(12):2161-2178 (co-authored with Tadashi Kumamoto et al.).
- 2021,"Principles of Ethical Consideration Required for Clinical Research Involving Children," Pediatrics International 63(3):248-259(co-authored with Kenji Matsui, Tomohide Ibuki, and Hidefumi Nakamura) ¡¥¢¨2016ǯ¡ØÆüËܾ®»ù²Ê³Ø²ñ»¨»ï¡Ù·ÇºÜÏÀʸ¤Î±ÑÌõ
- 2021, "Clinical Practice Guidance for Next-generation Sequencing in Cancer Diagnosis and Treatment (edition 2.1)," International Journal of Clinical Oncology 26:233-283(co-authored with Yoichi Naito et al.¡Ë.
- 2020,"The Principles of Revised Clinical Guidelines about Palliative Sedation Therapy of the Japanese Society for Palliative Medicine," Journal of Palliative Medicine 23(9):1184-1190 (co-authored with Kengo Imai et al.) .
- 2020, "Public Attitudes Toward the Secondary Uses of Patient Records for Pharmaceutical Companies' Activities in Japan," Therapeutic Innovation & Regulatory Science 54(3):701-708¡Êco-authored with Nakada Haruka et al.¡Ë.
- 2019, "Recommendations for Promoting International Multi-site Clinical Trials-from a Viewpoint of Ethics Review," Developing World Bioethics 19(4): 192-5 (co-authored with Nakada Haruka et al.).
- 2019,¡Ö¤¬¤ó°äÅÁ»Ò¥Ñ¥Í¥ë¸¡ºº¤È´µ¼Ô¡¦»Ô̱»²²è¡½ÀâÌÀƱ°Õ¥â¥Ç¥ëʸ½ñ¤ÎººÆÉ¥×¥í¥»¥¹¤«¤é³Ø¤Ö¡×¡Ø¼ðáçÆâ²Ê¡Ù24(2):183-193¡ÊÃæÅÄ ¤Ï¤ë²Â¡¦ÉðÆ£ ¹á¿¥¡¦Ê¡ÅÄ ÇîÀ¯¡¦²ÏÌî δ»Ö¤È¤Î¶¦Ãø¡Ë¡¥
- 2018,¡ÖÍø±×ÁêÈ¿´ÉÍý¤Ë´Ø¤¹¤ëÁ´¹ñ°åÎŵ¡´ØÄ´ºº¡¼Î×¾²¸¦µæË¡»Ü¹ÔÁ°¤Î¼ÂÂÖÇÄ°®¡×¡ØÎ×¾²ÌôÍý¡Ù49(6):213-218¡ÊÃæÅĤϤë²Â¡¦ÈÓÅĹá½ïΤ¡¦ÀîÀ¡¤ß¤æ¤ê¡¦µÈÅÄ²í¹¬¤È¤Î¶¦Ãø¡Ë.
- 2018,¡ÖÎÑÍý¿³ºº°Ñ°÷²ñ¤ÎÌò³ä¤òºÆ¹Í¤¹¤ë¡½È︳¼ÔÊݸ¤é¼Ò²ñŪ¿®Íê¤Ø¡×¡Øˡů³ØǯÊó¡Ê2017¡Ë¡Ù,23-41.
- 2018,¡Ö¤¬¤ó°åÎŤˤª¤±¤ëÎÑÍýŪÌäÂê¤ÎÆÃħ¤ò¹Í¤¨¤ë¡½¹ñÆâ¤ÎÎ×¾²ÎÑÍý¥±¡¼¥¹¥Ö¥Ã¥¯¤ÎʬÀϤ«¤é¡×¡ØÀ¸Ì¿ÎÑÍý¡Ù28(1):31-39¡ÊÃæÅÄ°¡´õ»Ò¡¦ÏÂÅÄÀéÊæ»Ò¡¦ÌÚ¼°Âµ®¤È¤Î¶¦Ãø¡Ë.
- 2018,¡Ö¿»ÜÀ߶¦Æ±¼£¸³¤Ë¤ª¤±¤ëÎÑÍý¿³ºº½¸Ì󲽤θ½¾õ¤È²ÝÂê¡×¡ØÎ×¾²ÌôÍý¡Ù49(4):159-196¡Ê°ðÌî¾´ÍΡ¦ÆâÅıÑÆ󡦰æ¾åͪÊ塦Æﲬ±Ñͺ¡¦Ä¹Ã«Àî½ã°ì¡¦¿¹²¼Åµ»Ò¡¦ºû·ª½ÓÇ·¤È¤Î¶¦Ãø¡Ë.
- 2018,¡Ö¡ÖÎ×¾²¸¦µæ¡¦¼£¸³³èÀ²½5¤«Ç¯·×²è2012¡×¤Ë¤ª¤±¤ëÎ×¾²¸¦µæÈ︳¼Ô¤Î¤¿¤á¤ÎÁêÃÌÁë¸ý¤Ë´Ø¤¹¤ë¼ÂÂÖÄ´ºº¡×¡ØÎ×¾²ÌôÍý¡Ù49(3):127-134¡ÊÉþÉôº´Ï»ҡ¦Ðòß·µ×¿Î»Ò¡¦»³ËÜÀ²»Ò¡¦¾¾°æ·ò»Ö¤È¤Î¶¦Ãø¡Ë.
- 2018,¡Ö·èÃǼçµÁ¤Ë¹³¤·¤Æ¡½Î×¾²ÎÑÍý¥±¡¼¥¹¸¡Æ¤¤Î²ÄǽÀ¡×¡Ø»Ù±ç¡Ù8: 55-67.
- 2018,¡ÖÆüËܤˤª¤±¤ëÎÑÍý¿³ºº°Ñ°÷²ñÀ©ÅÙ²þ³×¤ÎÆ°¸þ¡½¸¦µæÎÑÍý»Ø¿Ë¤«¤éÎ×¾²¸¦µæË¡¤Ø¡×¡Ø°åÎŤȼҲñ¡Ù28(1):79-91.
- 2018,¡Ö½ªËö´ü¤ËÀ¸¤¸¤ë°ì»þŪ¤Ê³ÐÀᦴ²²ò¤È¤½¤Î°ÕÌ£¡½ºßÂð¥Û¥¹¥Ô¥¹°ä²Ĵºº¤«¤é¡× ¡Ø»àÀ¸³Ø¡¦±þÍÑÎÑÍý¸¦µæ¡Ù23:75-96¡Ê½ô²¬Î»²ð¡¦Áêß·½Ð¡¦Æ£Ëܾ÷ɧ¡¦ÈÄÁÒ͵ª¤È¤Î¶¦Ãø¡Ë.
- 2018,¡ÈDevelopment, Reliability, and Validity of a Tool for the Assessment of Ethical Decision-making Skills among Health-related Researchers in Japan,¡ÉToho Journal of Medicine 4(1): 25-34 (co-authored with Akiko Nakada, Tomohide Ibuki, Taichi Kishi, Kenji Matsui, Atsushi Namiki).
- 2018,"Lessons for Reviewing Clinical Trials Using Induced Pluripotent Stem Cells: Examining the Case of a First-in-human Trial for Age-related Macular Degeneration," Regenerative Medicine 13(2):123-128 (co-authored with Kayo Takashima, Yusuke Inoue, Kaori Muto).
- 2018,¡Ö¥²¥Î¥à°åÎÅ¡¦¥²¥Î¥à²òÀϸ¦µæ¤Ë¤ª¤±¤ë¡Ö¶öȯŪ½ê¸«¡×³µÇ°¤ÎºÆ¹½ÃÛ¡½°Õ¿Þ¤Ë´ð¤Å¤¯Ê¬ÎàË¡¤ÎÄó°Æ¡×¡ØÎ×¾²ÌôÍý¡Ù49(1):43-49¡Ê»³ËÜ·½°ìϺ¡¦¾¾°æ·ò»Ö¡¦°Ë¿áͧ½¨¤È¤Î¶¦Ãø¡Ë
- 2018,¡ÖÀ½Â¤ÈÎÇä¸åÄ´ºº¤Ë¤ª¤±¤ëÈ︳¼ÔƱ°Õ¤ÈÎÑÍý¿³ºº¡½Á´¹ñɱ¡Ä´ºº¡×¡ØYAKUGAKU ZASSHI¡Ù138:63-71¡Ê¼¿¸¶¾°Ì¦¡¦Â¼¾å·ë¹á¡¦¾¾°æ·ò»Ö¤È¤Î¶¦Ãø¡Ë¡¥
- 2017,"Bridge the Gap: the Need for Harmonized Regulatory and Ethical Standards for Postmarketing Observational Studies," Pharmacoepidemiology and Drug Safety 26(11):1299-1306 (co-authored with Hisashi Urushihara, Louise Parmenter, Kenji Matsui, Nancy Dreyer).
- 2017,¡Ö°å³Ø¸¦µæ¤Î¸½¾ì¤«¤é¤ß¤¿¸Ä¿Í¾ðÊóÊݸîË¡²þÀµ¡½¡ÖŬÀÚ¤ÊƱ°Õ¡×¤È¤Ï¡×¡ØNBL¡Ù1103:34-41.
- 2017,¡Ö²È²¥Ë¡¼¥º¤«¤é¤ß¤¿ºßÂð´ËÏÂ¥±¥¢¤Î²ÝÂ꡽°ä²Ĵºº¤Ë¤ª¤±¤ë¼«Í³²óÅú¥Ç¡¼¥¿¤ÎʬÀϤ«¤é¡×¡ØÅ纬Âç³Ø¼Ò²ñÊ¡»ãÏÀ½¸¡Ù6:45-58.¡ÊÈÄÁÒ͵ª¤È¤Î¶¦Ãø¡Ë
- 2017,¡Ö¼«Âð¤Ç¤ÎÎÅÍܤϤʤ¼ÃæÃǤµ¤ì¤¿¤Î¤«¡½¡Ö¤ß¤ä¤®Êý¼°¡×¤ÎºßÂð´ËÏÂ¥±¥¢¤òÍøÍѤ·¤¿ºßÂð¥Û¥¹¥Ô¥¹°ä²Ĵºº¤«¤é¡×¡ØÅ纬Âç³Ø¼Ò²ñÊ¡»ãÏÀ½¸¡Ù6:33-44.¡ÊÁêß·½Ð¡¦Æ£Ëܾ÷ɧ¡¦½ô²¬Î»²ð¤È¤Î¶¦Ãø¡Ë
- 2016,¡Ö¾®»ù¤òÂоݤȤ¹¤ëÎ×¾²¸¦µæ¤Ë¤ª¤¤¤Æµá¤á¤é¤ì¤ëÎÑÍýŪÇÛθ¤Î¸¶Â§¡×¡ØÆüËܾ®»ù²Ê³Ø²ñ»¨»ï¡Ù120(8):1195-205¡Ê¾¾°æ·ò»Ö¡¦°Ë¿áͧ½¨¡¦Ãæ¼½¨Ê¸¤È¤Î¶¦Ãø¡Ë.
- 2016,¡ÖÂηÏŪ¤ÊÎÑÍý¿³ºº¤òÌܻؤ·¤Æ¡Ý¡ÖÎÑÍý¿³ºº¥Õ¥í¡¼¥·¡¼¥È¡×¤Î³«È¯¤È¤½¤ÎÆÃĹ¡×¡ØË̳¤Æ»À¸Ì¿ÎÑÍý¸¦µæ¡Ù4:1-17.¡Ê¾¾°æ·ò»Ö¤È¤Î¶¦Ãø¡Ë
- 2016,¡Ö»à¤Ë¤æ¤¯¿Í¡¹¤Ø¤Î¥±¥¢¤Ï¤É¤¦ÊѤï¤Ã¤¿¤«¡Ý¥Ý¥¹¥È¥ª¡¼¥×¥óǧ¼±¤Î»þÂå¤Ë¤ª¤±¤ë°åÎżҲñ³Ø¤Î²ÝÂê¡×¡ØÊÝ·ò°åÎżҲñ³ØÏÀ½¸¡Ù26(2): 21-30.
- 2014,"Handling Incidental Findings in Neuroimaging Research in Japan: Current State of Research Facilities and Attitudes of Investigators and the General Population,"Health Research Policy and Systems, 12:58(co-authored with Misao Fujita, Yoshinori Hayashi, Kyoko Takashima, Eisuke Nakazawa and Akira Akabayashi).
- 2014,¡Ö¹ñºÝ¶¦Æ±¸¦µæ¤ÎÎÑÍý¡½¸¦µæ¤Î¡ÖÍø±×¡×¤È¥°¥í¡¼¥Ð¥ë¤ÊÀµµÁ¡×¡Ø°å³Øů³Ø °å³ØÎÑÍý¡Ù32:96-100.
- 2014,¡Ö¥Õ¥£¡¼¥ë¥É¥ï¡¼¥«¡¼¤¬ÎÑÍý¿³ºº¤Ë½Ð²ñ¤¦¤È¤¡½°åΟ½¾ì¤Ë¤ª¤±¤ë¼ÁŪ¸¦µæ¤Î¡Öº¤Æñ¡×¡×¡Ø¼ÁŪ¿´Íý³Ø¥Õ¥©¡¼¥é¥à¡Ù6:9-17.
- 2014,¡ÉEthical Challenges for the Design and Conduct of Mega-biobanking from Great East Japan Earthquake Victims,"BMC Medical Ethics,15:55(co-authored with Kenji Matsui).
- 2014,¡Ö¸¦µæµ¬À©À¯ºö¤Î¤Ê¤«¤Î¼Ò²ñÄ´ºº¡½¡Ö¸¦µæ¼Ô¤Î¼«¼£¡×¤«¤é¡Ö¹ÔÀ¯»ØƳ¡×¤Ø¡©¡×¡Ø¼Ò²ñ¤ÈÄ´ºº¡Ù12:5-12.
- 2014,¡Ö¼Ò²ñÄ´ºº¤Î¡ÖÍø±×¡×¤È¤Ï²¿¤«¡½»³¸ý°ìÃˤÎÌäÂêÄ󵯤ò¤á¤°¤Ã¤Æ¡×¡Ø¼Ò²ñ³Ø¸¦µæ¡Ù93:5-28.
- 2013,¡Öɱ¡¶Ð̳°å¤Î¤¬¤ó´µ¼Ô¤Ø¤Îͽ¸å¹ðÃΤθ½¾õ¡½ºßÂð´ËÏÂ¥±¥¢°ä²Ĵºº¤«¤é¡×¡Ø´ËÏÂ¥±¥¢¡Ù23(5):411-5¡ÊÆ£Ëܾ÷ɧ¡¦Áêß·½Ð¡¦½ô²¬Î»²ð¤È¤Î¶¦Ãø¡Ë.
- 2012,¡ÖºßÂð¥Û¥¹¥Ô¥¹Ä´ºº¤Î´ë²è¤ÈÀ߷ס½Ä´ººÉ¼¥Ç¥¶¥¤¥ó¤Î´ÑÅÀ¤«¤é¡×¡ØÅ纬Âç³Ø¼Ò²ñÊ¡»ãÏÀ½¸¡Ù4: 17-30¡ÊÆ£Ëܾ÷ɧ¡¦½ô²¬Î»²ð¡¦Áêß·½Ð¤È¤Î¶¦Ãø¡Ë.
- 2012,"Ethical Issues of Placebo-Controlled Studies in Depression and a Randomized Withdrawal Trial in Japan:Case Study in the Ethics of Mental Health Research,"The Journal of Nervous and Mental Disease,200(3):255-9(co-authored with Maki M. Yamada and Kenji Matsui).
- 2010,¡Ö°å³Ø¸¦µæµ¬À©À¯ºö¤Î¿·¤¿¤ÊŸ³«¡½Ê¬Îö¤«¤éÅý¹ç¤Ø¡©¡×¡ØÊÝ·ò°åÎżҲñ³ØÏÀ½¸¡Ù21(1):32-8.
- 2010,"Unintended Consequences of 'Soft' Regulations:The Social Control of Human Biomedical Research in Japan,"International Journal of Japanese Sociology,19:4-17.
- 2010,"Research,Practice,and Innovative Therapy:On the Theoretical Models of Robert J. Levine"Asian Bioethics Review,2(3):229-39.
- 2008,¡Ö³×¿·Åª¼£ÎŤò¤É¤¦µ¬À©¤¹¤ë¤«¡½¸¦µæÎÑÍý¤«¤é¤Î¥¢¥×¥í¡¼¥Á¡×¡ØOrgan Biology¡Ù15(2):15-27.
- 2008,¡Ö¸½Âå¤Î´Ç¼è¤ê¤Ë¤ª¤±¤ë¡Ò¤ª·Þ¤¨¡ÓÂθ³¤Î¸ì¤ê¡½ºßÂð¥Û¥¹¥Ô¥¹°ä²¥¢¥ó¥±¡¼¥È¤«¤é¡×¡Ø»àÀ¸³Ø¸¦µæ¡Ù9:205-23.¡Ê½ô²¬Î»²ð¡¦Áêß·½Ð¡¦²¬Éô·ò¤È¤Î¶¦Ãø¡Ë
- 2007,¡Ö¸¦µæ¤È¿ÇÎŤò¶èÊ̤¹¤ëÆó¤Ä¤Î¥â¥Ç¥ë¡½¥Ø¥ë¥·¥ó¥Àë¸À¤«¤é¥Ù¥ë¥â¥ó¥È¡¦¥ì¥Ý¡¼¥È¤Ø¡×¡Ø°å³Øů³Ø °å³ØÎÑÍý¡Ù25:21-9
- 2007,¡Ö¸½Âå¤Î´Ç¼è¤ê¤È²È¡Ê¥¤¥¨¡Ë¡½ºßÂð¥Û¥¹¥Ô¥¹°ä²¥¢¥ó¥±¡¼¥È¤«¤é¡×¡Øʸ²½¡Ù71(1,2):46-64¡ÊÁêß·½Ð¡¦½ô²¬Î»²ð¡¦²¬Éô·ò¤È¤Î¶¦Ãø¡Ë
- 2006,¡ÖÎ×¾²»î¸³¤Î¥ê¥¹¥¯¤È¤½¤Î¸øÀµ¤ÊʬÇÛ¡½TGN1412»ö·ï¤Î¼Ò²ñÎÑÍý³ØŪ¹Í»¡¡×¡ØÎ×¾²É¾²Á¡Ù34(Suppl XXIV):149¡¾62.
- 2006,¡Ö°åÎÅÎÑÍý¤Ë¤ª¤±¤ë¡Ö¸¦µæ¤È¼£ÎŤζèÊ̡פÎÎò»ËŪ°ÕµÁ¡½ÆüÊÆÈæ³Ó¤Î»ëÅÀ¤«¤é¡×¡ØÎ×¾²ÎÑÍý³Ø¡Ù4:95¡¾115.
- 2006,¡ÖÀìÌ翦¤È¡Ö³«¤«¤ì¤¿¼«Î§¡×¡½¸å´ü¥Ñ¡¼¥½¥ó¥º°åÎżҲñ³Ø¤Î¼ÍÄø¡×¡Ø¼Ò²ñ³Ø¸¦µæ¡Ù79:85¡¾109.
- 2005,¡ÖÃÏ°è¼Ò²ñ¤Ë¤ª¤±¤ë¥Û¥¹¥Ô¥¹±¿Æ°¤Î¿¸µÅª·ÁÀ®¤ÈŸ³«¡½²¬»³¤Î»öÎã¤Ë¤ß¤ë3¤Ä¤Î¡ÖÍýÇ°¡×¤Î¶¥¹ç¡×¡ØÊÝ·ò°åÎżҲñ³ØÏÀ½¸¡Ù16(1):1¡¾12.
- 2004,¡ÖÀ¸Ì¿ÎÑÍýÀ¯ºö¤È¡Ö½¡¶µ¤ÎÀ¼¡×¡½Êƹñ¤Î¥¯¥í¡¼¥ó¡¦´´ºÙ˦¸¦µæ¤ò¤á¤°¤ëµÄÏÀ¤«¤é¡×¡ØÊ¡²»¤ÈÀ¤³¦¡Ù59(12):42¡¾7.
- 2004,¡ÖÀ¸Ì¿ÎÑÍý¤Î¡ÖÀ¤Â¯²½¡×¤È¤½¤Îµ¢·ë¡½½¡¶µÎÑÍý¤ÈÀ¤Â¯ÎÑÍý¤Î¤¢¤¤¤À¡×¡Ø¥«¥È¥ê¥Ã¥¯¼Ò²ñÊ¡»ã¸¦µæ¡Ù4:91¡¾119.
- 2003,¡Ö½¡¶µ¤ÈÀ¸Ì¿ÎÑÍý¡½½é´ü¥Ð¥¤¥ª¥¨¥·¥Ã¥¯¥¹¤Ë¤ª¤±¤ë¥¢¥á¥ê¥«¤Î½¡¶µÅªÅÁÅý¡×¡Ø¼Ò²ñ³Ø¸¦µæ¡Ù73:111¡¾34.
- 2002,¡ÖR.¥Õ¥©¥Ã¥¯¥¹¤Î¥Ð¥¤¥ª¥¨¥·¥Ã¥¯¥¹ÏÀ¡½À¸Ì¿ÎÑÍý¤Î¼Ò²ñ³Ø¤Ø¸þ¤±¤Æ¡×¡Ø¼Ò²ñ³ØǯÊó¡Ù31:83¡¾100.
²òÀ⡦ÁíÀâ
- 2024,¡Ö¿··¿¥³¥í¥Ê¥¦¥¤¥ë¥¹´¶À÷¾É¤ÈÎ×¾²ÎÑÍý¡×ÌÚß·µÁÇ·¡¦»Ö¿¿ÂÙÉס¦¹âµÜͲ𡦹±Æ£¶Ç¡¦µÜ²¼¸÷ÎáÊÔ¡Ø¥Û¥¹¥Ô¥¹´ËÏÂ¥±¥¢Çò½ñ2024 ¿··¿¥³¥í¥Ê¥¦¥¤¥ë¥¹´¶À÷¾É¡ÊCOVID-19¡Ë¤È´ËÏÂ¥±¥¢¡ÙÀij¤¼Ò, 23-27.
- 2023,¡Ö´µ¼Ô¤Î¡ÖºÇÁ±¤ÎÍø±×¡×¤È¤Ï²¿¤«¡½¶¹¤¤³µÇ°¤«¤é¹¤¤³µÇ°¤Ø¡×¡Ø´ËÏÂ¥±¥¢¡Ù33(5):375-379.
- 2023,¡ÖÎáÏÂ2ǯ¡¦ÎáÏÂ3ǯ¸Ä¿Í¾ðÊóÊݸîË¡²þÀµ¤ÎÍ×ÅÀ¡½Æ±°Õ¤Ë¤è¤é¤Ê¤¤¸¦µæÍøÍѤ¬µöÍƤµ¤ì¤ë3¤Ä¤Î¥Ñ¥¿¡¼¥ó¡×¡Ø¼ðáçÆâ²Ê¡Ù32(1):103-109.
- 2020,¡Ö¥¢¥É¥Ð¥ó¥¹¥±¥¢¡¦¥×¥é¥ó¥Ë¥ó¥°¤Ë¤ª¤±¤ë relational autonomy¡½²È²Âç»ö¤À¤è¤Í¡Á¤Ç¤Ï¤Ê¤¤¡×¡Ø´ËÏÂ¥±¥¢¡Ù30(5):399-402¡Ê¿¹ÅÄãÌ顦ԤÁýʸ¡¦¿¹²íµª¤È¤Î¶¦Ãø¡Ë.
- 2019,¡ÖÎ×¾²ÎÑÍý¤È¤Ïï¤Ë¤È¤Ã¤Æ¤ÎÌäÂ꤫¡©¡½ÂÐÏäε»Ë¡¤È¤·¤Æ¤Î¥¸¥ì¥ó¥Þ¡¦¥á¥½¥Ã¥É¡×¡ØCancer Board Square¡Ù5(3):98-101.¡ÊÊÔ½¸ÈǤκÆÏ¿¡Ë
- 2019,¡Ö¹½Â¤²½¤µ¤ì¤¿ÎÑÍý¥«¥ó¥Õ¥¡¥ì¥ó¥¹¤òÌܻؤ·¤Æ¡½¥¸¥ì¥ó¥Þ¡¦¥á¥½¥Ã¥É¤Ë³Ø¤Ö¡×¡ØCancer Board Square¡Ù5(3):106-120.¡ÊºÆÏ¿¡Ë
- 2019,¡ÖÎ×¾²ÎÑÍý¥µ¥Ý¡¼¥È¤Î¿·¤·¤¤Î®¤ì¡½°Ñ°÷²ñ¤«¤é¥Á¡¼¥à¤Ø¡¢¤½¤·¤ÆÂÐÏäÎʸ²½¤Ø¡×¡Ø´Ç¸î´ÉÍý¡Ù29(8):702-708.
- 2019,¡Ö¹½Â¤²½¤µ¤ì¤¿ÎÑÍý¥«¥ó¥Õ¥¡¥ì¥ó¥¹¤òÌܻؤ·¤Æ¡½¥¸¥ì¥ó¥Þ¡¦¥á¥½¥Ã¥É¤Ë³Ø¤Ö¡×¡Ø´Ç¸î´ÉÍý¡Ù29(8):710-725.
- 2019,¡ÖÍøÍÑÌÜŪ¤«¤é¹Í¤¨¤ë¸Ä¿Í¾ðÊóÊݸ°åÎÅ¡¦°å³Ø¸¦µæ¤«¤é¾¦¶ÈÍøÍѤޤǡסØNeurological Surgery ¡Ù47(2):241-248.
- 2018,¡ÖÎÑÍý¥³¥ó¥µ¥ë¥Æ¡¼¥·¥ç¥ó¥Á¡¼¥à¡Ê¥³¥ó¥µ¥ë¥¿¥ó¥È¤È¤·¤Æ¤Î¿ÇÎŲʲ£ÃÇ¥Á¡¼¥à£¡Ë¡×¡Ø¼£ÎÅ¡Ù101(1):72-75.
- 2018,¡ÖÎ×¾²¸¦µæË¡¤ÏÎ×¾²¸¦µæ¤ò¤É¤¦ÊѤ¨¤ë¤«¡½¡ÖÎ×¾²¸¦µæ¼Â»Ü´ð½à¡×¤È¤Ï¡×¡Ø´â¤È²½³ØÎÅË¡¡Ù45(7):1011¡¾1016.
- 2018,¡Ö¸Ä¿Í¾ðÊóÊݸîË¡²þÀµ¤È¸¦µæÎÑÍý»Ø¿Ë¡½¡Ö³Ø½Ñ¸¦µæ¤ÎÍѤ˶¡¤¹¤ë¡×¤È¤Ï¡×¡ØÆüËܾ®»ù·ì±Õ¡¦¤¬¤ó³Ø²ñ³Ø²ñ»ï¡Ù54(5):279-286¡ÊÆ£¸¶¹¯¹°¤È¤Î¶¦Ãø¡Ë.
- 2017,¡Ö¸Ä¿Í¾ðÊóÊݸîË¡²þÀµ¤ÈÎ×¾²¸¦µæ¡½Æ±°Õ¼ê³¤¤¬¡Öº¤Æñ¤Ê¾ì¹ç¡×¤È¤Ï¡×¡ØÌôÍý¤È¼£ÎÅ¡Ù45(suppl.2):s106-108.
- 2017,¡Ö²þÀµ¸Ä¿Í¾ðÊóÊݸîË¡¤È°å³Ø¸¦µæ¡½¡Ö¿·¤·¤¤¡×¸Ä¿Í¾ðÊó¤ÎÄêµÁ¤È¤Ï¡×¡ØÀº¿À²Ê¼£ÎųءÙ32(11):1529-33.
- 2016,¡Ö¿·¤·¤¤ÎÑÍý»Ø¿Ë¤ÏÀº¿À´Ç¸î¸¦µæ¤Ë²¿¤òµá¤á¤Æ¤¤¤ë¤Î¤«¡½Àº¿À¾ã³²¼Ô¤Î¡Ö¥ô¥¡¥ë¥Í¥é¥Ó¥ê¥Æ¥£¡×¤ò¹Í¤¨¤ë¡×¡ØÆüËÜÀº¿ÀÊÝ·ò´Ç¸î³Ø²ñ»ï¡Ù25(2): 70-77.
- 2016,¡Ö¤Ê¤¼Î×¾²»î¸³¤Ë´µ¼Ô»²²è¤¬É¬ÍפʤΤ«¡×¡Ø·ì±ÕÆâ²Ê¡Ù73(1):128-32.
- 2016,¡Ö¸¦µæ¼Ô¤Î¿·¤¿¤ÊÎÑÍýŪÀÕ̳¤È¤·¤Æ¤Î¡Ö¸¦µæ·ë²Ì¤ÎÊֵѡססطì±ÕÆâ²Ê¡Ù72(1):150-4.
- 2015,¡Ö¥²¥Î¥à¸¦µæ¤«¤é¤ß¤¿¡Ö¿Í¤òÂоݤȤ¹¤ë°å³Ø·Ï¸¦µæ¤Ë´Ø¤¹¤ëÎÑÍý»Ø¿Ë¡×¤Î°ÕµÁ¡½¡ÖÊñ³çƱ°Õ¡×¤ÎµöÍƾò·ï¤ò¤á¤°¤Ã¤Æ¡×¡ØÎ×¾²ÉÂÍý¥ì¥Ó¥å¡¼¡Ù154:65-72.
- 2015,¡Ö¸¦µæÎÑÍý»Ø¿Ë¤Ï¤É¤¦ÊѤï¤Ã¤¿¤«¡½´ðËܳµÇ°¤«¤éÍý²ò¤¹¤ë¡Ö¿Í¤òÂоݤȤ¹¤ë°å³Ø·Ï¸¦µæ¤Ë´Ø¤¹¤ëÎÑÍý»Ø¿Ë¡×¡×¡Ø»º¶È°å³Ø¥¸¥ã¡¼¥Ê¥ë¡Ù38(6):4-8.
- 2015,¡Ö¸¦µæÎÑÍý»Ø¿Ë¤Ï¤É¤¦ÊѤï¤Ã¤¿¤«¡½´ðËܸ¶Â§¤«¤éÍý²ò¤¹¤ë¡Ö¿Í¤òÂоݤȤ¹¤ë°å³Ø·Ï¸¦µæ¤Ë´Ø¤¹¤ëÎÑÍý»Ø¿Ë¡×¡×¡Ø¥¯¥ê¥Ë¥«¥ë¥ê¥µ¡¼¥Á¡¦¥×¥í¥Õ¥§¥Ã¥·¥ç¥Ê¥ë¥º¡Ù50:28-34.
- 2015,¡Ö¼Á¤Î¹â¤¤ÎÑÍý¿³ºº¤È¤Ï²¿¤«¡½ÎÑÍý¿³ºº°Ñ°÷²ñ¤ÎǧÄêÀ©Å٤˸þ¤±¤Æ¡×¡ØÌôÍý¤È¼£ÎÅ¡Ù43(6):767-70.
- 2015, ¡Ö¡Ö¿Í¤òÂоݤȤ¹¤ë°å³Ø·Ï¸¦µæ¤Ë´Ø¤¹¤ëÎÑÍý»Ø¿Ë¡×¤ÎÍ×ÅÀ¡×¡ØCANCER BOARD of the BREAST¡Ù1(2): 55-8.¡Ê»³ËÜÀº°ìϺ¤È¤Î¶¦Ãø¡Ë
- 2014,¡Ö°åÌôÉʤÎÎ×¾²»î¸³¤ÈÎÑÍý¡½¥é¥ó¥À¥à²½¤È¥×¥é¥»¥Ü¤ÎµöÍƾò·ï¡×¡Ø°åÌô¥¸¥ã¡¼¥Ê¥ë¡Ù50(8):75-8.
- 2014,¡ÖºÆÀ¸°åÎŤÎÎ×¾²¸¦µæ¤ÈÎÑÍý¡½¡Ö°åÎų׿·¡×¤Ï¸¦µæ¤«¿ÇÎŤ«¡×¡Ø°åÌô¥¸¥ã¡¼¥Ê¥ë¡Ù50(8):87-90¡Ê»³ËÜ·½°ìϺ¤È¤Î¶¦Ãø¡Ë.
- 2013,¡Ö¡Ö»à¤Ë¤æ¤¯¿Í¡¹¤È¤Î¥³¥ß¥å¥Ë¥±¡¼¥·¥ç¥ó¡×¤ò»Ù¤¨¤ë¤â¤Î¡×¡Ø´ËÏÂ¥±¥¢¡Ù23(6):438-41.
- 2013,¡ÖÎ×¾²¸¦µæ¤Ë¤ª¤±¤ë¥ê¥¹¥¯¡¦¥Ù¥Í¥Õ¥£¥Ã¥Èɾ²Á¡×¡Ø°å³Ø¤Î¤¢¤æ¤ß¡Ù246(8):539-44.
- 2013,¡ÖÆüËܤÎÎ×¾²¸¦µæ¥¬¥Ð¥Ê¥ó¥¹¡½¤½¤ÎÎò»Ë¤ÈÆÃħ¤òõ¤ë¡×¡ØÎ×¾²ÌôÍý¡Ù44(2):131-5.
- 2010,¡Ö¸¦µæÎÑÍý¤Î¥Õ¥í¥ó¥Æ¥£¥¢¡½¥Ø¥ë¥·¥ó¥Àë¸À¤ÎÎò»Ë¤È¸½ºß¡×¡Ø½Û´ÄÀ©¸æ¡Ù31(3):177-81.
- 2010,¡ÖÎ×¾²¸¦µæ¤Ë¤ª¤±¤ëÍø±×ÁêÈ¿¡½¹ñÆâ³°¤Î¸¦µæÎÑÍý¥¬¥¤¥É¥é¥¤¥ó¤ÎÆ°¸þ¡×¡ØÀº¿À¿À·Ð³Ø»¨»ï¡Ù112(11):1130-5.
- 2010,¡Ö¸¦µæÎÑÍý¥¬¥¤¥É¥é¥¤¥ó¤Î¶áǯ¤ÎÆ°¸þ¡½¡ÖÎ×¾²¸¦µæ¤Ë´Ø¤¹¤ëÎÑÍý»Ø¿Ë¡×¤Î²þÀµ¤òÃæ¿´¤Ë¡×¡ØÆâʬÈ硦ÅüǢɡ¦Âå¼ÕÆâ²Ê¡Ù31(1):81-9.
- 2010,¡Ö¸¦µæÎÑÍý¤Ï¤Ê¤¼É¬Íפ«¡½Î×¾²¸¦µæ¤ÎÎò»Ë¤Ë³Ø¤Ö¡×¡Ø¥Ó¥ª¥Õ¥£¥ê¥¢¡Ù23:71-74.
- 2009,¡Ö¥³¥ß¥å¥Ë¥Æ¥£¤ò´ðÈפȤ¹¤ë¥¹¥Ô¥ê¥Á¥å¥¢¥ë¥±¥¢¡½´ËÏÂ¥±¥¢¤Ø¤Î¸ø½°±ÒÀ¸Åª¥¢¥×¥í¡¼¥Á¡×¡Ø´ËÏÂ¥±¥¢¡Ù19(1):39-42¡¥
½ñɾ¡¦»öŵ¹àÌÜÅù
- 2024,¡Ê½ñɾ¡Ë¡Ö¿·¤·¤¤»þÂå¤ÎÀìÌç²È¤Îºß¤êÊý¤ò¼¨¤¹¡×¡ÊÈøÆ£À¿»ÊÃø¡Ø´µ¼Ô¤Î°Õ»×·èÄê¤Ë¤É¤¦´Ø¤ï¤ë¤«¡©¡§¥í¥¸¥Ã¥¯¤ÎÅý¹ç¤È¼ÂÁ©¤Î¤¿¤á¤Îµ»Ë¡¡Ù¡Ë¡Ø½µ´©°å³Ø³¦¿·Ê¹¡Ù3551:6.
- 2023,¡ÊÂÐÃÌ¡Ë¡Ö¿Íʸ¡¦¼Ò²ñ²Ê³Ø¤ÎÃ諤ÇÎ×¾²¤Î¤â¤ä¤â¤ä¤òÀ°Íý¤¹¤ë¡×¡Ê¿¹ÅÄãÌé¤È¤Î¶¦Ãø¡Ë¡Ø½µ´©°å³Ø³¦¿·Ê¹¡Ù3526:1-2.
- 2023,¡ÊŤÃÌ¡Ë¡Ö¡Ö¥¹¥Ô¥ê¥Á¥å¥¢¥ê¥Æ¥£¡×¤È¸À¤ï¤º¤Ë»à¤äĶ±ÛŪ¤Ê¤³¤È¤ò¸ÀÍդˤ¹¤ë¡×¡Ø»Ù±ç¡Ù13:168-219¡ÊÉâ¥ö빬Â塦°æ¸ý¹â»Ö¤È¤Î¶¦Ãø¡Ë¡¥
- 2023,¡Ê½ñɾ¡Ë¡Ö¥¨¥ó¥É¥ª¥Ö¥é¥¤¥Õ¥±¥¢¤Î̤Íè¤ò¼¨¤¹¡×¡Ê¥¢¥é¥ó¡¦¥±¥ì¥Ï¡¼Ãø¡¤ÃÝÇ·Æâ͵ʸ¡¦ËÙÅÄæâ»Ò´ÆÌõ¡Ø¥³¥ó¥Ñ¥Ã¥·¥ç¥óÅԻԡݸø½°±ÒÀ¸¤È½ªËö´ü¥±¥¢¤ÎÍ»¹ç¡Ù ¡Ë¡ØÆüËÜ¥¨¥ó¥É¥ª¥Ö¥é¥¤¥Õ¥±¥¢³Ø²ñ»ï¡Ù7(1):78-79.
- 2023,¡Ê½ñɾ¡Ë¡Ö°å³Ø¸¦µæ¤Ë´Ø¤ï¤ë¤¹¤Ù¤Æ¤Î¿Í¤Î¤¿¤á¤Ë¡×¡Ê¾¾°æ·ò»Ö´Æ½¤¡¦ÊÔÃø¡¿»³ËÜ·½°ìϺ¡¦°Ë¿áͧ½¨¡¦°æ¾åͪÊåÊÔÃø¡ØÁêÃÌ»öÎ㤫¤é¹Í¤¨¤ë¸¦µæÎÑÍý¥³¥ó¥µ¥ë¥Æ¡¼¥·¥ç¥ó¡Ù¡Ë¡Ø°å³Ø¤Î¤¢¤æ¤ß¡Ù284(8):621.
- 2023,¡Ê½ñɾ¡Ë¡ÖÎ×¾²°å¤Ë¤è¤ë¡Ö¤Ò¤È¤ê³ØºÝ¸¦µæ¡×¤Î¼êËܤȤ·¤Æ¡×¡Ê¿¹ÅÄãÌé¡Ø³ ½ªËö´ü¤Î¶ìÄˤ¬¤Ê¤¯¤Ê¤é¤Ê¤¤»þ¡¢²¿¤¬ÁªÂò¤Ç¤¤ë¤Î¤«¡©¡Ý¶ìÄË´ËÏ¤Τ¿¤á¤ÎÄÃÀÅ¡Ê¥»¥Ç¡¼¥·¥ç¥ó¡Ë¡Ø½µ´©°å³Ø³¦¿·Ê¹¡Ù3503:6.
- 2023, ¡ÊºÂÃ̲ñ¡Ë¡ÖÎ×¾²ÎÑÍý¤ò²þ¤á¤Æ¹Í¤¨¤ë¡½ÁÈ¿¥¤È¤·¤Æ¼è¤êÁȤߡ¢Ê¸²½¤òº¬ÉÕ¤«¤»¤ë¤¿¤á¤Ë¡×¡Ø´Ç¸î´ÉÍý¡Ù33(1):42-49¡ÊÀ¶¿åůϺ¡¦½Ð¼½ß»Ò¤È¤Î¶¦Ãø¡Ë.
- 2022,¡Ê¹Ö±éÏ¿¡Ë¡Ö¼ÂÁ©¼Ô¤Î¤¿¤á¤Î¸¦µæÎÑÍýÆþÌç¡×¡Ø½¸ÃÄÀº¿ÀÎÅË¡¡Ù38(2):260-270.
- 2022,¡Ê¹Ö±éÏ¿¡Ë¡Ö¸Ä¿Í¾ðÊóÊݸîË¡²þÀµ¤Ëȼ¤¦¸¦µæÎÑÍý»Ø¿Ë²þÀµ¤Ë¤Ä¤¤¤Æ¡×¡Ø¥ê¡¼¥¬¥ë¥Þ¥¤¥ó¥É¡Ù446:34-73.
- 2021,¡ÊÂÐÃÌ¡Ë¡Ö¸½Âå¼Ò²ñ¤È°åÎŤÎÀÜÅÀ¤òɳ²ò¤¯¡½¼Ò²ñ³Ø¼Ô¤È°åÎÅÀìÌ翦¤Î¶¨Æ¯¤¬Ë¤°¡¢ÎÑÍýŪ¤Ê°åΟ½¾ì¤Î¤¢¤ê¤è¤¦¤È¤Ï¡×¡Ø´Ç¸î´ÉÍý¡Ù31(8):635-641¡ÊÀгÀÌ÷»Ò¤È¤Î¶¦Ãø¡Ë.
- 2020,¡ÊºÂÃ̲ñ¡Ë¡Ö¤¬¤ó°åÎŤËɬÍפÊÎ×¾²ÎÑÍý¡×¡Ø½µ´©°å³Ø³¦¿·Ê¹¡Ù3392:1-2¡ÊÀ¶¿åÀé²Â»Ò¡¦ºù°æ¤Ê¤ª¤ß¤È¤Î¶¦Ãø¡Ë¡¥
- 2020,¡Ê¥³¥á¥ó¥È¡Ë¡Ö¡Öɾ²Á¤Î»þÂå¡×¤ò¤É¤¦¤ß¤ë¤«¡½°åÎÅʬÌî¤Ç¤ÎÆ°¸þ¤Ë¨¤·¤Æ¡×¡Ø¼Ò²ñ³ØǯÊó¡Ù49:57-61.
- 2020,¡Ê½ñɾ¡Ë¡Öʸ²½¤È¤·¤Æ¤Î½ªËö´ü¥±¥¢¡×¡Ê¡ØÀ¸¤¤é¤ì¤ë»à¡ÙÉþÉôÍΰìÃø¡Ë¡Ø»Ù±ç¡Ù10:251-252.
- 2019,¡Ö¥¸¥ì¥ó¥Þ¡¦¥á¥½¥Ã¥É¤Ë¤è¤ëÎ×¾²ÎÑÍý¥«¥ó¥Õ¥¡¥ì¥ó¥¹¡¼Í½¸å¤¬»Ä¤ê¾¯¤Ê¤¤»þ´Ö¤Î¤Ê¤«¡¢²È²¤È¤ÎÌ̲ñ¤òµñÈݤ·Â³¤±¤ë´µ¼Ô¤ÈÌ̲ñ¤ò´õ˾¤¹¤ë²È²¤Î´õ˾¤Ë¤É¤¦±þ¤¨¤ë¤«¡×¡ØCancer Board Square¡Ù5(3):121-135¡Ê¼éÅÄμ¡¦À¶¿åÀé²Â»Ò¡¦°ì²È¹ËË®¡¦µÜÅIJÂÂå»Ò¡¦Î¤¸«³¨Íý»Ò¡¦°ð¼ľ»Ò¤È¤Î¶¦Ãø¡Ë.
- 2019,¡Ö¥¸¥ì¥ó¥Þ¡¦¥á¥½¥Ã¥É¤òÍѤ¤¤¿ÎÑÍý¥«¥ó¥Õ¥¡¥ì¥ó¥¹¡¼¡Ö"¿©¤Ù¤é¤ì¤ë¤è¤¦¤Ë¤Ê¤ê¤¿¤¤"¤È¤¤¤¦´õ˾¤¬¶¯¤¤´µ¼Ô¤ËÂФ·¤Æ¡¢¤É¤¦´Ø¤ï¤ì¤Ð¤è¤¤¤«Ê¬¤«¤é¤Ê¤¯¤Ê¤Ã¤¿¡×»öÎã¡Ø´Ç¸î´ÉÍý¡Ù29(8):726-736¡Ê°ð¼ľ»Ò¡¦µÜÅIJÂÂå»Ò¡¦Î¤¸«³¨Íý»Ò¡¦°ì²È ¹ËË®¡¦À¶¿åÀé²Â»Ò¡¦¹âÅÄÇîÈþ¤È¤Î¶¦Ãø¡Ë¡¥
- 2019, "Letter in Reply to: 'Therapeutic Misconception and the Role of the Research Ethics Committee'," Regenerative Medicine (co-authored with Takashima K, Inoue Y, Muto K)
- 2019, "Taipei Declaration on Advance Care Planning: A Cultural Adaptation of End-of-Life Care Discussion," Journal of Palliative Medicine (co-authored with Lin CP et al.)
- 2019,¡ÊLetter to the Editor¡Ë¡ÖµßµÞÎΰè¤Ë¤ª¤±¤ë¥¯¥é¥¹¥¿¡¼¥é¥ó¥À¥à²½Èæ³Ó»î¸³¤È¥¤¥ó¥Õ¥©¡¼¥à¥É¡¦¥³¥ó¥»¥ó¥È¡×¡ØÆüËܵߵްå³Ø²ñ»¨»ï¡Ù30(3):90-91¡ÊÈ«»³Ì¹°¤È¤Î¶¦Ãø¡Ë
- 2018,¡ÊºÂÃ̲ñ¡Ë¡Ö°åÎÅ¡¦°å³Ø¸¦µæ¤Ë¤ª¤±¤ë¸Ä¿Í¾ðÊóÊݸî¤ÈÍø³èÍѤÎ̤Í衽°åÎÅ¡¦°å³Ø¸¦µæ¤Î¸½¾ì¤«¤é¡×¡ØÏÀµæ¥¸¥å¥ê¥¹¥È¡Ù24:142-166¡ÊÊƼ¼¢¿Í¡¦ÈÄÁÒÍÛ°ìϺ¡¦¹õÅÄÃι¨¡¦¹âÌÚÍøµ×¡¦µÈÊö¹ÌÊ¿¤È¤Î¶¦Ãø¡Ë.
- 2017,¡Ê½ñɾ¡Ë¡Ö¡Ö¥°¥ì¡¼¥¾¡¼¥ó¡×¤ÇǺ¤àÁ´¤Æ¤Î°åÎżԤΤ¿¤á¤Ë¡×¡Ê¿¹ÅÄãÌé¡Ø½ªËö´ü¤Î¶ìÄˤ¬¤Ê¤¯¤Ê¤é¤Ê¤¤»þ¡¢²¿¤¬ÁªÂò¤Ç¤¤ë¤Î¤«¡©¡Ý¶ìÄË´ËÏ¤Τ¿¤á¤ÎÄÃÀÅ¡Ê¥»¥Ç¡¼¥·¥ç¥ó¡Ë¡Ø½µ´©°å³Ø³¦¿·Ê¹¡Ù3238:6.
- 2017,¡Ê½ñɾÏÀʸ¥ê¥×¥é¥¤¡Ë¡Ö̤Íè¤Î¡Ø»à¤Ë¤æ¤¯²áÄø¡Ù¸¦µæ¤Î¤¿¤á¤Ë¡×¡ØÊÝ·ò°åÎżҲñ³ØÏÀ½¸¡Ù28(1):68-70.
- 2017,¡ÖÀ¸Ì¿ÎÑÍý¡×¡Ø¼Ò²ñ³ØÍýÏÀ±þÍÑ»öŵ¡Ù´ÝÁ±, 164,165.
- 2017,¡Ö²þÀµ¸Ä¿Í¾ðÊóÊݸîË¡¤ÏÎ×¾²¸¦µæ¤Ë¤É¤Î¤è¤¦¤Ê±Æ¶Á¤òÍ¿¤¨¤ë¤Î¤«¡×¡Ø½µ´©°å³Ø³¦¿·Ê¹¡Ù3207:4¡ÊÆ£¸¶¹¯¹°¤È¤Î¶¦Ãø¡Ë
- 2016,¡Ê¥³¥é¥à¡Ë¡Ö»à¼Ô¤Îɽ¾Ý¡×ÀîÅçÂçÊ塦¶áÆ£·ÃÊԡؤϤ¸¤á¤Æ¤Î»àÀ¸¿´Íý³Ø¡½¸½Âå¼Ò²ñ¤Ë¤ª¤¤¤Æ¡¤»à¤È¤È¤â¤ËÀ¸¤¤ë¡Ù¿·Í˼Ò,207.
- 2016, ¡Ê¥³¥á¥ó¥È¡Ë¡Ö¡Ö¼«Ê¬¤ò¼º¤¦¤³¤È¡×¤È¤É¤¦¸þ¤¹ç¤¦¤«¡×ÃÝÇ·Æâ͵ʸ¡¦Àõ¸¶Áï»ÒÊÔ¡ØÁÓ¼º¤È¤È¤â¤ËÀ¸¤¤ë¡½ÂÐÏ乤ë»àÀ¸³Ø¡Ù¥Ý¥é¡¼¥Î½ÐÈÇ,154-159.
- 2015,¡Ê¹Ö±éÏ¿¡Ë¡Ö¤³¤ì¤«¤é¤ÎÎ×¾²¸¦µæµ¬À©¤ò¹Í¤¨¤ë¡½²¤ÊƤθ½¾õ¤«¤é³Ø¤Ù¤ë¤³¤È¡×¡Ø¥ê¡¼¥¬¥ë¥Þ¥¤¥ó¥É¡Ù363:1-43.
- 2014,¡Ê¹Ö±éÏ¿¡Ë¡Ö¡Ø¥Ç¥£¥ª¥Ð¥ó»ö·ï¡Ù¤«¤é¹Í¤¨¤ëÎ×¾²¸¦µæ¤ÎÎÑÍý¤Èµ¬À©¡×¡Ø¥ê¡¼¥¬¥ë¥Þ¥¤¥ó¥É¡Ù351:1-56.
- 2012,¡Ê½ñɾ¡Ë¡ÖÉ©»³Ë¡Ø¥é¥¤¥Õ¥µ¥¤¥¨¥ó¥¹À¯ºö¤Î¸½ºß¡½²Ê³Ø¤È¼Ò²ñ¤ò¤Ä¤Ê¤°¡Ù¡×¡Ø¼Ò²ñ¤ÈÎÑÍý¡Ù27: 208-9.
- 2010,¡ÊɾÅÁ¡Ë¡Ö°¤Éô¶³»Ì¤ÎÀ¸³¶¡×°¤Éô¶³»ÌÃø¡¿ÃÝÇ·Æâ͵ʸÊԡؼ·Å¾¤Ó Ȭµ¯¤¿²¤¿¤¤ê ¤¤¤Î¤Á¤Î¾Ú¤·¡½¥¯¥Á¥Þ¥¦¥¹¤ÇÄÖ¤ë¶Ú¥¸¥¹¡¦¼«Î©À¸³è20ǯ¡Ù¿·¶µ½ÐÈǼÒ,314-22.
- 2010,¡Êʸ¸¥¾Ò²ð¡Ë¡Ö¥ì¥Í¡¼¡¦C¡¦¥Õ¥©¥Ã¥¯¥¹¡ØÀ¸Ì¿ÎÑÍý¤ò¤ß¤Ä¤á¤Æ¡Ù¾®ÎÓ¿¼÷»ÒÊÔÃø¡Ø¥é¥¤¥Õ¥¹¥È¡¼¥ê¡¼¡¦¥¬¥¤¥É¥Ö¥Ã¥¯¡½¤Ò¤È¤¬¤Ò¤È¤Ë²ñ¤¦¤¿¤á¤Ë¡Ùº·²åÌî½ñ±¡,96-9.
- 2009,"Classes of Activities in Clinical Laboratories:Practice, Research, or Else?" Asian Bioethics Review,1(3):281-4(co-authored with Kenji Matsui).
- 2009,¡Ê¥³¥é¥à¡Ë¡Ö¥Û¥¹¥Ô¥¹¡¦´ËÏÂ¥±¥¢¡×¡Ö°Â³Ú»à¡×¡Ö»à¤Î¥¿¥Ö¡¼²½¡×À¶¿åůϺ´Æ½¤¡¿²¬Éô·ò¡¦ÃÝÇ·Æâ͵ʸÊԡؤɤ¦À¸¤ ¤É¤¦»à¤Ì¤«¡½¸½¾ì¤«¤é¹Í¤¨¤ë»àÀ¸³Ø¡ÙµÝÀý½ñ±¡,47,117,140.
- 2007,¡Ê¹àÌܼ¹É®¡Ë¡ÖÎ×¾²»î¸³¤ÈÈ︳¼Ô¤ÎÊݸî¡×¡Ø±þÍÑÎÑÍý³Ø»öŵ¡Ù´ÝÁ±,312-313.
- 2006,¡ÖÈ︳¼ÔÊݸ¥¹¥Æ¥à¤Î¹½Ãۤ˸þ¤±¤Æ¡×¡ØÎ×¾²ÎÑÍý³Ø¡Ù4:3-8.
- 2004,¡Ê½ñɾ¡Ë¡Ö¥ì¥Í¡¼¡¦C¡¦¥Õ¥©¥Ã¥¯¥¹¡ØÀ¸Ì¿ÎÑÍý¤ò¤ß¤Ä¤á¤Æ¡½°åÎżҲñ³Ø¼Ô¤ÎȾÀ¤µª¡Ù¡×¡ØÊÝ·ò°åÎżҲñ³Ø²ñÏÀ½¸¡Ù14(2):65-6.
ËÝÌõ
- 2007, À¸Ì¿ÎÑÍýÉ´²Ê»öŵËÝÌõ´©¹Ô°Ñ°÷²ñÊÔ¡¦ÆüËÜÀ¸Ì¿ÎÑÍý³Ø²ñÊÔ½¸¶¨ÎÏ¡ØÀ¸Ì¿ÎÑÍýÉ´²Ê»öŵ¡Ù´ÝÁ±.¡Ê¡Ö°åÎÅÎÑÍý¡Ê¥è¡¼¥í¥Ã¥Ñ¤ÎÎò»Ë¡§¸½Âå¡Ë¡×¤Î¡Ö¥¤¥®¥ê¥¹¡×¡Ö¥¢¥¤¥ë¥é¥ó¥É¶¦Ï¹ñ¡×¡Ö¥í¥·¥¢¡×¤òôÅö¡Ë
¥ê¥ó¥¯
- ¹ñΩ¤¬¤ó¸¦µæ¥»¥ó¥¿¡¼¤¬¤óÂкö¸¦µæ½êÀ¸Ì¿ÎÑÍý¡¦°å»öË¡¸¦µæÉô
- ¹ñΩ¤¬¤ó¸¦µæ¥»¥ó¥¿¡¼¸¦µæ»Ù±ç¥»¥ó¥¿¡¼À¸Ì¿ÎÑÍýÉô
- ÅìµþÂç³Ø°å²Ê³Ø¸¦µæ½ê ¸ø¶¦À¯ºö¸¦µæʬÌî
- Î×¾²ÎÑÍý¥Í¥Ã¥È¥ï¡¼¥¯ÆüËÜ
- ÀŲ¬Âç³ØÇÀ³ØÉô ů³Ø¸¦µæ¼¼
- ÁÖ½©²ñ²¬Éô°å±¡
- NPOË¡¿Í·ò¹¯¤Èɤ¤¤Î¸ì¤ê ¥Ç¥£¥Ú¥Ã¥¯¥¹¡¦¥¸¥ã¥Ñ¥ó
ºÇ½ª¹¹¿·»þ´Ö¡§2022ǯ12·î06Æü 14»þ36ʬ35ÉÃ
62542 counts since Apr 2007
ËÜ¥µ¥¤¥ÈµºÜ¾ðÊó¡¢¥ê¥ó¥¯¤Ë¤Ä¤¤¤Æ